Culture Biosciences is a biotechnology startup that operates in the field of large-scale biomanufacturing. The company's primary service is to design, monitor, and analyze high-throughput bioprocessing experiments for its clients. This is done remotely using Culture's integrated bioreactor platform, a system that allows for the cultivation of cells in a controlled environment.

The company's clients are typically other businesses in the biotechnology sector, such as Joyn Bio and Modern Meadow, who require large-scale biomanufacturing capabilities. These clients benefit from Culture's services by being able to scale down their processes, as evidenced by the company's white paper on technical transfer.

Culture Biosciences operates in the biotechnology market, a sector that is seeing increasing demand for large-scale biomanufacturing solutions. The company recently announced its Series B financing, indicating a positive response from investors and a potential for growth.

The business model of Culture Biosciences is service-based. The company makes money by providing bioprocessing experiment services to its clients. This includes the design, monitoring, and analysis of these experiments, which are conducted on the company's integrated bioreactor platform.

Keywords: Biotechnology, Large-Scale Biomanufacturing, High-Throughput Bioprocessing, Integrated Bioreactor Platform, Service-Based Business Model, Bioprocessing Experiment Services, Technical Transfer, Scale-Down Processes, Series B Financing, Biotechnology Market.